Add Formweb to your mobile device
Search results for:
darbepoetin alfa
darbepoetin alfa
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| Aranesp | SOLUTION, INJECTABLE | 25 mcg/0.42 mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 40 mcg/0.4 mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 60 mcg/0.3 mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 100 mcg/0.5 mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 100 mcg/mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 150 mcg/0.3 mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 200 mcg/0.4 mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 300 mcg/0.6 mL | |
| Aranesp Albumin Free | SOLUTION, INJECTABLE | 300 mcg/mL |
Last updated: Jan. 9, 2024
- Black Box Warning: Mortality, serious CV events, tumor progression or recurrence
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.